Bifogade filer
PDF
Kurs
-0,72%
Likviditet
1,40 MDKK
Kalender
| Tid* | ||
| 2026-02-03 | N/A | Bokslutskommuniké 2025 |
| 2025-10-21 | N/A | Kvartalsrapport 2025-Q3 |
| 2025-07-22 | N/A | Kvartalsrapport 2025-Q2 |
| 2025-04-29 | N/A | Kvartalsrapport 2025-Q1 |
| 2025-03-12 | N/A | Årsstämma |
| 2025-02-05 | N/A | Bokslutskommuniké 2024 |
| 2024-10-22 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-23 | - | Kvartalsrapport 2024-Q1 |
| 2024-03-13 | - | Årsstämma |
| 2024-03-13 | - | X-dag ordinarie utdelning EMBLA 0.00 DKK |
| 2024-03-12 | - | Årsstämma |
| 2024-01-30 | - | Bokslutskommuniké 2023 |
| 2023-10-24 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-25 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-13 | - | X-dag ordinarie utdelning EMBLA 0.00 DKK |
| 2023-03-10 | - | Årsstämma |
| 2023-01-31 | - | Bokslutskommuniké 2022 |
| 2022-10-25 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-21 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-26 | - | Kvartalsrapport 2022-Q1 |
| 2022-03-09 | - | X-dag ordinarie utdelning EMBLA 0.00 DKK |
| 2022-03-08 | - | Årsstämma |
| 2022-02-01 | - | Bokslutskommuniké 2021 |
| 2021-10-26 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-22 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-27 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-09 | - | X-dag ordinarie utdelning EMBLA 0.00 DKK |
| 2021-03-08 | - | Årsstämma |
| 2021-02-02 | - | Bokslutskommuniké 2020 |
| 2020-10-27 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-23 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-30 | - | Kvartalsrapport 2020-Q1 |
| 2020-03-13 | - | X-dag ordinarie utdelning EMBLA 0.15 DKK |
| 2020-03-12 | - | Årsstämma |
| 2020-02-04 | - | Bokslutskommuniké 2019 |
| 2019-10-22 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-25 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-30 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-08 | - | X-dag ordinarie utdelning EMBLA 0.14 DKK |
| 2019-03-07 | - | Årsstämma |
| 2019-02-05 | - | Bokslutskommuniké 2018 |
| 2018-10-24 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-25 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-25 | - | Kvartalsrapport 2018-Q1 |
| 2018-03-09 | - | X-dag ordinarie utdelning EMBLA 0.13 DKK |
| 2018-03-08 | - | Årsstämma |
| 2018-02-05 | - | Bokslutskommuniké 2017 |
| 2017-10-24 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-25 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-27 | - | Kvartalsrapport 2017-Q1 |
| 2017-03-10 | - | X-dag ordinarie utdelning EMBLA 1.95 DKK |
| 2016-03-11 | - | X-dag ordinarie utdelning EMBLA 0.12 DKK |
| 2016-03-10 | - | Årsstämma |
| 2016-02-02 | - | Bokslutskommuniké 2015 |
| 2015-10-22 | - | Kvartalsrapport 2015-Q3 |
| 2015-07-23 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-29 | - | Kvartalsrapport 2015-Q1 |
| 2015-03-12 | - | Årsstämma |
| 2015-02-05 | - | Bokslutskommuniké 2014 |
| 2014-10-24 | - | Analytiker möte 2014 |
| 2014-10-23 | - | Kvartalsrapport 2014-Q3 |
| 2014-07-25 | - | Analytiker möte 2014 |
| 2014-07-24 | - | Kvartalsrapport 2014-Q2 |
| 2014-04-30 | - | Analytiker möte 2014 |
| 2014-04-29 | - | Kvartalsrapport 2014-Q1 |
| 2014-03-14 | - | Årsstämma |
| 2014-02-05 | - | Bokslutskommuniké 2013 |
| 2013-10-24 | - | Analytiker möte 2013 |
| 2013-10-23 | - | Kvartalsrapport 2013-Q3 |
| 2013-07-24 | - | Kvartalsrapport 2013-Q2 |
| 2013-04-24 | - | Kvartalsrapport 2013-Q1 |
| 2013-03-15 | - | Årsstämma |
| 2013-02-06 | - | Bokslutskommuniké 2012 |
| 2012-11-28 | - | Kapitalmarknadsdag 2012 |
| 2012-11-27 | - | Kapitalmarknadsdag 2012 |
| 2012-10-24 | - | Analytiker möte 2012 |
| 2012-10-23 | - | Kvartalsrapport 2012-Q3 |
| 2012-07-25 | - | Kvartalsrapport 2012-Q2 |
| 2012-04-24 | - | Kvartalsrapport 2012-Q1 |
| 2012-03-16 | - | Årsstämma |
| 2012-02-08 | - | Bokslutskommuniké 2011 |
| 2011-10-27 | - | Kvartalsrapport 2011-Q3 |
| 2011-07-28 | - | Kvartalsrapport 2011-Q2 |
| 2011-03-04 | - | Årsstämma |
Beskrivning
| Land | Island |
|---|---|
| Lista | Large Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Announcement no. 28/2022
2 May 2022
Transactions in relation to share buyback program
On 14 February 2022, Össur hf. initiated a share buyback program ("Program"), see Company Announcement no. 05/2022.
The purpose of the Program is to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Capital Allocation Policy. The Program will end no later than 23 December 2022, but the Company is entitled to discontinue the Program at any time. The Company may purchase up to 2,000,000 shares under the Program, corresponding to 0.47% of the current share capital. The total consideration for shares purchased under the Program shall not exceed USD 10 million.
The following transactions have been made under the Program in the period 25 April 2022 - 29 April 2022.
Transactions
Date No. of Avg. purchase Transaction
shares price in DKK value in DKK
25 April 2022 23,364 38.89 908,635
26 April 2022 28,950 37.56 1,087,264
27 April 2022 23,733 36.14 857,782
28 April 2022 34,000 35.23 1,197,708
29 April 2022 22,400 35.01 784,323
Total 132,447 36.51 4,835,711
Össur has acquired 642,413 shares under the Program at the average price of DKK 38.25. Following the above transactions, Össur holds 1,268,780 shares, corresponding to 0.30% of the Company's total share capital.
The Program on Nasdaq Copenhagen is carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission's delegated regulation 2016/1052.
Further information
Edda Lára Lúðvígsdóttir, Investor Relations Director, eludvigsdottir@ossur.com,+354 844 4759
Össur press releases by e-mail
If you wish to receive Össur press releases by e-mail, please register at http://www.ossur.com/investors
About Össur
Össur (Nasdaq Copenhagen: OSSR) is a global leader in non-invasive orthopaedics that helps people live a Life Without Limitations. A recognized "Technology Pioneer" with a rich 50-year history, Össur focuses on improving people's mobility through the delivery of innovative technologies in Prosthetics and Bracing & Supports. Significant investment in research and development have led to over 2,000 patents, award-winning designs, successful clinical outcomes, and consistently strong market positions. Össur is signatory to the UN Global Compact, UN Women's Empowerment Principles, contributes to the UN Sustainable Development Goals and became Carbon Neutral in 2021. Össur operates globally and employs around 4,000 employees. www.ossur.com